Ganaxolone Treatment in Children With Fragile X Syndrome
Fragile x Syndrome
About this trial
This is an interventional treatment trial for Fragile x Syndrome focused on measuring fragile x syndrome, ganaxolone, anxiety, attention, pediatric
Eligibility Criteria
Inclusion Criteria:
- molecular documentation of FMR1 full mutation
- ages 6-17 yrs, inclusive
- sexually active subjects are required to use a medically acceptable form of birth control
Exclusion Criteria:
- non-English or Spanish speaking subjects
- concomitant systemic steroid, vigabatrin, felbamate and ketoconazole
- changes in medications within last 2 months
- clinically unstable medical disease, progressive CNS disease/disorder
- history of recurrent status epilepticus
- unwilling to withhold grapefruit or grapefruit juice for the duration of the study
- actively suicidal
Sites / Locations
- M.I.N.D. Institute at University of California at Davis Medical Center
- Antwerp University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Ganaxolone then Placebo
Placebo then Ganaxolone
Participants first received ganaxolone. They were first titrated up to the 12 milligram per kilogram (mg/kg) three times daily (tid) during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received placebo for a duration of 6 weeks (from week 8 to 14).
Participants first received placebo. They were first titrated up to the 12 mg/kg tid during a 2-week titration phase, then maintained on that dose for an additional 4 weeks. After a washout period of 2 weeks, participants received ganaxolone for a duration of 6 weeks (from week 8 to 14).